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Abstract 
The development of synthetic vascular grafts for coronary artery bypass is challenged by 
insufficient endothelialization, which exposes to the risk of thrombosis, and lack of native 
cellular constituents, which favours pathological remodelling. Here, an bifunctional 
electrospun poly(ε-caprolactone) (PCL) scaffold with potential for synthetic vascular graft 
applications is presented. This scaffold incorporates two tethered peptides: the osteopontin-
derived peptide (Adh) on the ‘luminal’ side and a heparin-binding peptide (Hep) on the 
‘abluminal’ side. Additionally, the ‘abluminal’ side of the scaffold is seeded with saphenous 
vein-derived pericytes (SVPs) as a source of pro-angiogenic growth factors. The Adh peptide 
significantly increase endothelial cell adhesion, while the Hep peptide promote accumulation 
of vascular endothelial growth factor (VEGF) secreted by SVPs. SVPs increase endothelial 
migration both in a transwell assay and a modified scratch assay performed on the PCL 
scaffold. Seeding of SVPs on the ‘abluminal’/Hep side of the scaffold further increase 
endothelial cell density, indicating a combinatory effect of the peptides and pericytes. Lastly, 
SVP-seeded scaffolds are preserved by freezing in a xeno-free medium, maintaining good 
cell viability and function. In conclusion, this engineered scaffold combines patient-derived 
pericytes and spatially organized functionalities, which synergistically increase endothelial 
cell density and growth factor retention. 
1. Introduction 
According to the World Health Organization, coronary artery disease is the leading cause of 
death and disability in the world. Autologous vascular bypass is a common intervention 
aimed at re-establishing blood flow to the cardiac tissue in patients for whom balloon 
angioplasty and/or stenting are not viable options. However, in patients with vascular 
complications or requiring multiple bypasses, autologous vessels might not be available or 
  
sufficiently healthy. Tissue engineered vascular grafts (TEVGs) are an attractive alternative 
to natural vessels. In recent years, many different approaches have been tested both in vitro 
and in vivo to implement the design of new TEVG, in particular of small diameter vessels 
below the critical diameter of 6 mm (for reviews see [1,2]). In these approaches, cells are 
seeded on biodegradable vascular scaffolds prepared with a variety of techniques, including 
hydrogel self-assembly, particulate-leaching, and electrospinning. In particular, 
electrospinning of biodegradable materials, such as poly(ε-caprolactone (PCL) has been used 
extensively to obtain biocompatible vascular scaffolds with tuneable functional properties 
and suitable mechanical properties.[3] 
Despite remarkable progress, TEVG design remains a challenge in the field of tissue 
engineering due to the poor performance of non-natural vessels in terms of thrombosis and 
long-term patency. Largely, graft failure is associated with delayed and insufficient re-
endothelialization of the ‘luminal’ surface which exposes the scaffold surface to the blood 
stream, leading to platelet activation. In order to reduce the risk of failure, the TEVGs should 
resist thrombosis while promoting a quick re-endothelialization from the neighbouring 
vascular tissue.[4] Previous studies have demonstrated that the pre-implantation seeding of 
TEVGs, including ‘luminal’ seeding of endothelial cells, dramatically improves their 
performance.[5] More recent studies suggest that the role of the transplanted cells is mainly to 
provide the initial stimuli to accelerate recruitment of host cells on to the graft, through the 
release of growth factors and cytokines promoting endothelial cell migration, before being 
displaced by the host cells.[6] In particular, autologous mesenchymal stem cells (MSCs) have 
shown remarkable anti-thrombogenic properties,[7] as also demonstrated in clinical trials.[8,9] 
The adventitia of large vessels contains clonogenic pericytes, which are now considered the 
primitive progenitors of MSCs. We have recently set up a Good Manufacturing Practises 
(GMP)-compliant standard operating procedure (SOP) for isolation and expansion of 
  
pericytes from remnants of saphenous vein grafts used for coronary artery bypass 
surgery.[10,11] Saphenous vein-derived pericytes (SVPs) paracrinally promote endothelial cell 
proliferation and network formation in vitro and improve neoangiogenesis and hemodynamic 
recovery, when transplanted in models of hindlimb ischemia or myocardial infarction.[10,12,13] 
Additionally, SVPs display a privileged immune-modulatory phenotype and could therefore 
be used for allogeneic purposes.[14] However, the exceptional characteristics of SVPs have 
never been harnessed for tissue engineering of vascular grafts. In this in vitro proof-of 
concept study, we present a tissue engineered construct composed of an advanced biomaterial 
seeded with SVPs to recreate the adventitial niche and provide a source of angiocrine factors 
promoting the graft endothelialization. We hypothesize that this scaffold will see application 
in the design of TEVG and we will therefore term the two sides of the scaffold as ‘luminal’ 
and ‘abluminal’ in relation to their potential positioning within a TEVG. 
The PCL scaffold produced to support the SVP growth was designed to present spatially 
defined functionalities, aimed at enhancing and promoting SVP properties. PCL is a 
biodegradable and readily processable, FDA approved polymer that can be electrospun alone 
or blended with other polymers to form small diameter vascular grafts that are mechanically 
sound and amenable to endothelialization.[3,15,16] 
We have previously described an advanced electrospinning technique to obtain dual 
functionalized PCL scaffolds for cartilage repair.[17] Applying the same technique, we here 
created a PCL scaffold presenting a spatially organized distribution of two tethered peptides, 
an osteopontin derived adhesion (Adh) peptide on the ‘luminal’ side, to favour endothelial 
cell attachment; and a heparin binding peptide (Hep) on the ‘abluminal’ side, where it is 
ideally placed to coordinate the pericyte-produced growth factors. The Adh peptide is a 
cryptic binding motif of osteopontin that is exposed following thrombin cleavage typically 
observed in vascular damage. Adh binds to integrin α4β1[18] and α9β1[19] on endothelial cells 
  
and induces cell adhesion and maturation, when provided as a soluble factor[20] or patterned 
on a surface.[21] Furthermore, when conjugated to a PEG based hydrogel, Adh displayed a 
strong pro-angiogenic activity both in vitro[22] and in vivo.[22,23] Importantly, Adh has been 
shown to reduce macrophage attachment and promote their differentiation towards the 
reparative phenotype.[24,25] The Hep peptide is a small amphiphilic sequence that binds 
heparin and can improve endothelial cell function and angiogenesis.[26-29] As previously 
demonstrated, the tethering of heparin to vascular scaffolds improves their performance by 
retaining and presenting growth factors, such as VEGF and FGF2.[30] The presence of the 
Hep peptide on the ‘abluminal’ side of the scaffold will be crucial to capture and release the 
SVP-produced growth factors over time.  
This study describes an original approach to the design of scaffolds aimed at TEVG, 
enhancing the activity of the patient-derived cells seeded on it by introducing multiple bio-
functionalizations aimed at improving endothelial cell adhesion and growth factor 
availability. Here we focus on the in vitro study of the synergistic contribution of the SVP-
released factors and tethered functionalities by studying the biological mechanisms 
underlying the process of re-endothelialization.  
2. Results  
2.1 Scaffold preparation and characterization 
In this study, we characterized a proof-of-concept model of a peptide-functionalized PCL 
scaffold for tissue engineered vascular graft applications. The spatial organisation of the 
scaffold was engineered to present osteopontin-derived peptide (Adh) on the ‘luminal’ side 
and the heparin-binding peptide (Hep) on the ‘abluminal/adventitial’ side (Figure 1a). The 
advanced electrospinning procedure applied allows precise control of the spatial localization 
of the two peptide-conjugated polymers and the creation of a dual peptide scaffold presenting 
  
two opposing concentrations of the peptides, as shown in Figure 1b. The resulting 
electrospun mats were imaged by SEM, showing the consistency of the fibre morphology 
between the unconjugated scaffolds and the Hep/Adh scaffold (Figure 1c and Figure S5). 
Indeed, the fibre diameters were similarly distributed between different scaffolds (CTL: 
1.40±0.59µm; Hep: 0.82±0.18 µm; Adh: 1.20±0.47 µm; Hep/Adh: 0.99±0.39 µm and 
1.52±0.33 µm on either side). 
2.2 Functional activity of conjugated peptides  
The capacity of the Hep peptide to bind heparin and retain growth factors was studied by 
incubating the different PCL scaffolds with FITC-heparin and SVP-released GFP-tagged 
VEGF. Indeed, Hep-PCL and Hep/Adh -PCL showed increased fluorescence when incubated 
with FITC heparin compared to the control-PCL, indicating a preferential binding of heparin 
to the Hep peptide (Figure 2a). Furthermore, human SVPs were transfected with a plasmid 
expressing VEGF in fusion with GFP and incubated with control scaffold, Hep or Hep/Adh-
PCL in presence of heparin. Results showed that the retention of SVP-secreted VEGF was 
highly improved by the Hep peptide (Figure 2b). VEGF loaded Hep-conjugated scaffold 
were also shown to promote endothelial cell density, as compared to unloaded scaffolds and 
control scaffolds loaded with VEGF (Figure 2c and Figure 2d).  
Next, the presentation and functionality of Adh peptide was tested by plating HUVECs on the 
different scaffolds. Adhesion of endothelial cells was assessed by measuring the cell density 
on the scaffold, confirming that Adh-conjugated scaffolds displayed increased endothelial 
cell number (Figure 3).  
2.3 Cooperative effect of pericyte seeding and scaffold functionalization  
  
We evaluated the combined effect of the conjugation of the peptides to the scaffold and the 
seeding of the pericytes on the ‘abluminal’/Hep side, by comparing the endothelial cell 
density in the presence of each factor or their combination. 
A non-contact co-culture system of SVPs and HUVECs was created on both control PCL and 
Hep/Adh scaffolds by seeding the SVPs on the ‘abluminal’/Hep side and the HUVECs on the 
‘luminal’/Adh side of the scaffolds. As a control, HUVECs were cultured in absence of SVPs 
on both types of scaffold. Quantification of endothelial cell nuclei showed that the 
combination of the presence of pericytes and the conjugates had a significantly higher impact 
on endothelial coverage, as compared to each of the factors alone (Figure 4). 
2.4 Effect of pericytes on endothelial cell migration 
Pericytes are known to release a plethora of pro-angiogenic factors; hence we hypothesize 
that SVPs can improve the migration of endothelial cells. This is particularly relevant in the 
context of vascular grafting to encourage the migration of the endothelial cells from 
neighbouring vessels and reach the complete endothelialization of the lumen of the implanted 
scaffolds. Indeed, the transwell migration assay showed that the presence of pericytes in the 
lower chamber increased the migration of endothelial cells by 2.5 times in the 8 hours 
timeframe of the assay (Figure 5a and Figure 5b). 
Furthermore, we confirmed an increased wound closure by endothelial cells in a modified 
scratch assay performed in a co-culture system on PCL where the endothelial monolayer was 
interrupted by forming a gap with a polydimethylsiloxane (PDMS) mask (Figure 5c). 
Fluorescence imaging of the whole ‘luminal’ side of the scaffolds indicated increased 
presence of endothelial cells in the gap of the scaffolds pre-seeded with pericytes the 
‘abluminal/Hep’ (Figure 5d-g). Quantification of the mean fluorescence within the gap 
  
showed an average increase of 67.6±20.8% in endothelial cell density (P<0.05; N = 3) in the 
SVP-seeded scaffolds.  
2.5 Freezing of pericytes-coated scaffolds 
The effective deployment of the devised scaffold for the development of clinically relevant 
TEVG is highly dependent on its resilience to freezing/thawing for preservation/delivery 
purposes. We tested the feasibility of this approach by freezing the SVP-seeded Hep/Adh 
PCL scaffolds using a cell therapy-approved xeno-free freezing medium and assessing their 
viability and functionality after thawing. AlamarBlue® assay results showed that the 
scaffolds thawed after 14 days of freezing could be efficiently recovered and that over 65% 
of the pericytes were viable (Figure 6a). Despite the 50% reduction in SVP cell number 
(Figure 6b), the cells were still adherent (Figure 6d) and were able to stimulate EC density 
to a level comparable to the fresh SVPs (Figure 6c and Figure 6d). These results indicate the 
potential for long-term storage of the pre-prepared vascular grafts based on our scaffold. 
 
3. Discussion 
In this work we describe how the biomaterial functionality may be integrated with the 
properties of the cells seeded on it to develop an implemented biomaterial with improved 
endothelialization properties for TEVG applications. In this proof-of-concept study, we 
characterized a polymer-based scaffold presenting a dual peptide functionalization, enabling 
the differential localization of each peptide and therefore recapitulating tissue-like 
organization. As compared to classical bulk post-fabrication functionalization, our previously 
reported sequential electrospinning method provides better control and homogeneity of the 
functionalization distribution,[17] which more closely resembles the complexity of the 
  
precisely layered vascular tissue. In particular, we demonstrated that the presentation of the 
adhesive peptide Adh on the ‘luminal’ side increased endothelial cell attachment and density. 
These results are in line with the previously reported pro-angiogenic capacity of the Adh 
peptide both in vitro and in vivo.[20-22] Earlier studies reported that the surface modification of 
electrospun PCL scaffolds with the ubiquitous cell adhesion peptide RGD accelerated the 
endothelialization process in rabbit carotid artery graft.[31] Of note, the Adh peptide is derived 
from the enzymatic cleavage of the pro-angiogenic protein osteopontin, typically occurring at 
the site of vascular damage [32] and is therefore preferentially recognized by endothelial cell 
expressed integrins, limiting the anchorage of inflammatory cells.[22,24,25] 
The versatile method of electrospinning allows for the introduction of multiple functionalities 
in a single step process; therefore, bi-functional scaffolds could be produced including a 
second functionality, the Hep peptide, on the ‘abluminal’ side of the scaffold and in direct 
contact with the seeded SVPs. The saphenous vein derived pericytes regulate the endothelial 
cell function by releasing a large array of pro-angiogenic and pro-proliferative growth factors 
and cytokines, which have been shown to contribute to their therapeutic action in vivo.[10,12] 
Our results showed that the Hep peptide was able to efficiently bind fluorescent heparin and 
to increase the retention of the SVP-produced VEGF, increasing EC adhesion and density on 
the scaffold. These results confirm that the conjugation of Hep to PCL does not impair its 
heparin binding capacity[26,29] and suggest that its localization is optimal to adsorb and release 
growth factors on the scaffold. Indeed, the Hep peptide provides versatile coordinating 
capacity for a variety of pro-angiogenic growth factors presenting a heparin-binding domain, 
such as VEGF, angiopoietin and fibroblast growth factor-2 (FGF-2) [33]. We hypothesize that 
the formation of a heparin-bound growth factor reservoir might prove advantageous in vivo. 
The transplanted SVPs would initially secrete growth factors, attracting the host endothelium 
  
to the graft and replenishing the reservoir within the scaffold. Later, the stored growth factors 
might play a role in supporting the growth of host cells, after they replaced the SVPs.[6,34] 
Interestingly, the proposed scaffold could represent an alternative route of delivery to harness 
and potentiate the therapeutic properties of the SVPs. In the context of vascular grafts, several 
autologous cell types have been tested to improve the clinical outcome of TEVGs, including 
human skeletal muscle pericytes[35] and bone marrow derived mesenchymal cells.[9] However, 
despite the encouraging results, cell sourcing often poses an additional burden to the patient. 
The SVPs can be isolated from the leftover of the saphenous vein obtained during the cardiac 
bypass procedure, avoiding additional harvesting procedure and providing a readily available 
source of therapeutic cells from the same cardiac patients that might need the synthetic grafts 
in the future. Furthermore, using adventitial pericytes is the more specific manner to recreate 
the adventitial stem cell niche. Previous studies have shown that integrity of the adventitial 
and perivascular layers is essential for durability of vascular grafts.[36] Our GMP-compliant 
SOPs for SVP isolation and expansion has now been transferred to NHS Blood and 
Transplant unit which is a recognized authority for cell therapy manufacture in UK. This 
represents a step forward to clinical use of SVPs. Accordingly, we have shown that the SVP-
seeded scaffolds can be preserved in cell therapy-compatible freezing medium maintaining its 
functionality. Potentially, this would allow the preparation and storage of seeded TEVG as an 
off-the-shelf product, especially if we consider the privileged immune-modulatory phenotype 
of SVPs, suggesting their amenability to allogeneic transplantations.[14] Previous efforts 
aimed at obtaining off-the-shelf frozen cell-derived TEVG were limited to the preparation of 
a devitalized frozen scaffold.[37]  
As previously discussed, the cells seeded on the vascular graft promote the migration and 
proliferation of the local endothelial cells on the scaffold surface. Indeed, the ability of SVPs 
to promote endothelial cell coverage was preserved on the scaffold, as demonstrated by the 
  
increased number of endothelial cells detected in the co-culture settings.[10] Interestingly, 
SVPs were also able to influence endothelial cell migration, as evidenced by the increased 
gap closure and direct migration. In previous studies the SVPs conditioned medium showed 
no effect on endothelial cell migration,[10] indicating that the co-culture is a necessary 
condition for the release of pro-migratory factors by SVPs and supporting the beneficial 
effect of using SVPs in a scaffold-based approach. The effect of SVPs was increased by the 
presence of the peptides as demonstrated by the confluent endothelial monolayer obtained on 
Hep/Adh scaffolds seeded with SVPs.  
In summary, we report the preparation of a pericytes-seeded, peptide-conjugated electrospun 
scaffold presenting two spatially distinct functionalities, which intrinsically promote 
endothelialisation and co-adjuvate the pro-angiogenic and pro-migratory effects of the 
pericytes. In vitro, the scaffold herein described displayed a great degree of endothelialization 
and a distinctive potential for rapid in vivo exploitation, due to its resilience to freezing, the 
biocompatibility of the material and the GMP quality of the cells employed. It is interesting 
to note that in this work we employed the well-established endothelial cell model (HUVECs) 
which is of foetal origin; it remains to be established if the observed effects could be even 
more prominent utilizing cells from an ageing donor. 
We envision that the developed proof-of-concept scaffold could be implemented into a 
superior synthetic vascular graft, presenting both immediate and long term pro-migratory 
stimuli aimed at accelerating endothelialization. It is expected that the fast recruitment of 
endothelial cells from the neighbouring vessels solicited by the attractive presence of SVPs 
and the adhesive luminal surface would improve the thrombo-resistance in the short term and 
in the long run contribute to a reduced neointima hyperplasia thanks to the sustained release 
of pro-angiogenic growth factors from the reservoir created by the heparin-binding 
compartment. 
  
 
4. Experimental section  
Cell culture and co-culture conditions 
SVPs were obtained as previously described by digestion of vein leftover, obtained from 
cardiac bypass patients with their signed consent, as approved by the Bath Research Ethics 
Committee (approval number 06/Q2001/1970).[10] Briefly, venous samples were minced and 
digested with Liberase 2 (Roche, Basel, Switzerland). SVPs were derived from 
CD34positive/CD31negative cells isolated by magnetic bead–assisted cell sorting (MACS, 
Miltenyi).[10,12] 
Both human umbilical vein endothelial cells (HUVECs, Lonza) and SVPs were cultured in 
endothelial growth medium (EGM2, Lonza); SVPs were seeded on gelatin and fibronectin 
coated plates, as previously described.[10,12] 
Scaffold preparation and characterization 
Peptides (Hep: CGGGAAALRKKLGKA and Adh: SVVYGLRGGC) were synthesized on a 
Symphony Quartet peptide synthesizer (Protein Technologies, Inc., Tucson, Arizona) using 
standard Fmoc chemistry on the solid-phase. The crude products were purified using a 
reverse phase preparative high performance liquid chromatography (HPLC, Shimadzu) 
running a mobile phase gradient of 95% deionized water and 5% acetonitrile (ACN) to 100% 
ACN with 0.1% (v/v) trifluoroacetic acid (TFA). The Phenomenex C18 Gemini NX column 
was 150 x 21.2 mm and had a 5 μm pore size. The resulting pure products were confirmed by 
electrospray ionization mass spectrometry (ESI-MS) (Figure S1). A terminal cysteine plus a 
glycine spacer was incorporated in the peptide design to allow for attachment to PCL. 
  
The peptide-functionalized scaffolds were prepared following a previously established 
protocol.[17] In brief, to first prepare the polymer-peptide conjugates, the terminal hydroxyl 
groups of PCL (MW14 kDa) were modified with a heterobifunctional linker p-
maleimidophenyl isocyanate (PMPI) to generate maleimide-functionalized PCL. Then, the 
modified PCL was dissolved in DMF with either the Hep or Adh peptide, and allowed to 
react overnight in the presence of a few drops of DIPEA. The resulting conjugates where 
washed extensively with water to remove unbound peptide and peptide attachment was 
confirmed by nuclear magnetic resonance (NMR, Figure S2). Fluorescently labelled 
conjugates were obtained by reacting the available amines of the peptide with either 
fluorescein isothiocyanate (FITC) or NHS-rhodamine in DMF with a few drops of DIPEA. 
Next, 1% (w/v) Hep- and Adh–PCL was blended with 11% (w/v) unmodified PCL (MW 80 
kDa) in 1,1,1,3,3,3,-hexafluoro-2-propanol (HFIP) and electrospun either as a single peptide 
mats (CTL, Hep or Adh) or as a dual peptide scaffold (Adh/Hep). Scanning electron 
microscopy (SEM) was used to verify the fiber size and the scaffold architecture. 
Scaffolds were electrospun on a custom built device as previously reported.[38] Briefly, the 
electrospinning device consisted of a faraday cage (Phnoenix Mechano Limited, UK), two 
high voltage sources (ETPS Limited, UK), and two syringe pumps (NE-1010 High Pressure 
Syringe Pump, World Precision Instruments, UK), providing a constant polymer flow 
through the needle (blunt needle, 18GTerumo, Scientific Laboratory Supplies Ltd, Wilford, 
UK). The positive voltage was applied to the needle, whereas the collector was on a negative 
bias. High voltage was controlled by a custom made software based on labview (Empa, Swiss 
Federal Laboratories of Materials Science and Technology, St. Gallen, Switzerland) via a 
labjack interface (labjack, RS components, UK). All mono-functionalised scaffolds and 
control scaffolds were spun at 11/-5kV, 2mL·h-1 flow rate and a distance of 11 cm. Bi-
functional scaffolds (Adh/Hep) were produced with a modified method, employing two 
  
syringe pumps combining the two polymers via teflon tubing and a three way valve. By this, 
continuous spinning without changing syringes or polymer solutions could be guaranteed and 
bi-functional scaffolds were not subjected to delamination.  
Fibre diameter was measured with ImageJ software, based on SEM images, for each 
condition, 50-100 fibres were measured.  
Scaffolds were sterilized in 70% (v/v) ethanol for 30 minutes and incubated with 1% (w/v) 
bovine serum albumin for 3 hours prior to further applications. 
Peptide functionality on the scaffold 
To assess the binding of heparin, 12 mm discs were cut out from the different scaffolds and 
incubated with 5 μg/ml of heparin-FITC (Life Technologies) overnight at room temperature 
and then thoroughly washed. For VEGF binding, SVPs were seeded at 70% confluence and 
transfected with 0.5 μg of plasmid encoding for VEGF165 tagged with GFP (RG229662, 
OriGene), using Fugene at 3:1 ratio (Promega). After 6 hours transfection medium was 
removed and replaced with EGM2 (Lonza) and the transfected cells were incubated with 
different PCL scaffolds for 48 hours. Expression of the transgene was verified by qPCR, 
using QuantStudio 6 Real time PCR (LifeTechnologies) and the following primers: F-
AGGGCAGAATCATCACGAAT and R-AGGGTCTCGATTGGATGGCA (Figure S3). 
Binding of fluorescent proteins to the scaffolds was quantified by fluorescence microscope 
imagining. Three images of each scaffold were taken at 4x with the same camera setting and 
quantified as mean grey value (mean fluorescence) using FIJI software. This measure is linearly 
correlated to the fluorescent protein concentration (Figure S4). 
For the functional characterization of VEGF binding to control and Hep scaffolds, 8mm 
round scaffolds were cut and incubated for 2 hours at 37C with heparin (100µg/ml) and 
VEGF (200µg/ml) or just heparin as control. After a 30 min wash, 1 x 105 HUVECs were 
  
plated on each scaffold in EBM medium containing 0.5% (v/v) FBS. AlamarBlue® was 
performed as described above at 48 hours.[39] 
To test the influence of peptide functionalization on endothelial coverage, 1 x 105 HUVECs 
were seeded on each 8mm scaffold for 48h. Scaffolds were then fixed, stained with Wheat 
Germ Agglutinin-AlexaFluor 488 (WGA-488) and DAPI and 4 imaged (4x) of each scaffold 
were obtained and quantified. Higher magnification pictures (10x and 20x) were used as 
representative images. 
Co-culture on PCL scaffolds 
To test the cumulative effect of the peptides and the SVPs co-culture, control and Hep/Adh 
scaffolds were cut in 18 mm discs, locked in 24 well plate CellCrown™ (Sigma) inserts, and 
1.5 x 105 Wheat Germ Agglutinin-AlexaFluor 568 (WGA-568) stained SVPs were seeded 
and let to attach for 2 hours on the Hep side. Then, 2.5 x 105 WGA-488 stained HUVECs 
were seeded on the Adh side by inverting the scaffold inside the CellCrowns™. Cells were 
cultured for 48 hours and then fixed and stained with DAPI. Number of nuclei was counted in 
three random fields acquired at 4x, using FIJI (ImageJ). Each experiment included at least 
two biological replicates and was repeated three independent times; each experiment was 
normalized to the control (control PCL without SVPs).  
For gap closure experiment, a modification of the protocol above was applied wherein the 1.5 
x 105 SVPs and 7.5 x 105 HUVECs were seeded on 6 well plate CellCrown™. Prior to 
HUVECs seeding a 0.5 mm PDMS barrier was locked in the middle of the PCL mat to 
prevent adhesion of the endothelial cells in the central region. After 3 hours, non-adherent 
HUVECs were washed away and the barrier was removed. Migration into the gap was 
assessed at 48 hours by fluorescence imaging of the whole well and quantified as mean grey 
value in 10 random fields of the gap area (n=3). 
  
Transwell migration assay 
Prior to the start of migration, 1.5 x 104 SVPs were seeded on each well of a 24 well plate in 
500 μl of complete medium overnight. Transwell® inserts (Corning, 8 μm pores) were coated 
with fibronectin on the lower side and 5 x 104 HUVECs were added to the upper chamber 
and let migrate for 8 hours. Next, remaining cells in the upper chamber were removed and 
cells migrated to the lower side of the transwell were fixed, stained with DAPI and counted. 
Five random fields were imaged at 4x for each four biological replicates; the results are 
normalised to the spontaneous migration values. The average of seven independent 
experiments is reported.  
Scaffold freezing and recovery 
Hep/Adh scaffolds were cut in 14 mm discs and seeded with 1.5 x 105 SVPs. After 24 hours 
half of the samples were frozen in CTS™ Synth-a-Freeze® Cryopreservation Medium 
(LifeTechnologies), a GMP manufactured, chemically defined, protein-free freezing medium 
and half underwent AlamarBlue® measurement, as described above. After 14 days, frozen 
scaffolds were recovered in full medium for 24 hours and then tested with AlamarBlue® in 
the same conditions used for the controls. Results were normalized to the fluorescence value 
of AlamarBlue® incubated with unseeded scaffolds. After measurement cells were fixed and 
stained with WGA-488. 
To test the post-freezing functionality, recovered scaffolds were inserted in CellCrown™ 
supports and 50,000 WGA-488 stained HUVECs were plated on the ‘luminal’ side of each 
scaffold. The number of adherent HUVECs was quantified after 48 hours. 
Statistical analysis 
  
Each experiment was repeated 3-7 independent times (N) and 2-4 technical replicates (n) 
were included within each repeat. Data were analysed using GraphPad Prism 5 and are 
expressed as mean ± SD. For pairwise comparison, unpaired t-test was performed. For 
multiple comparisons, one-way ANOVA was performed, followed by Bonferroni post-test. A 
P<0.05 was considered significant. 
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Figure 1. Characterization of the engineered scaffold for blood vessel graft applications. 
The bifunctional scaffold is composed of electrospun peptide-conjugated polycaprolactone 
(PCL) fibres seeded on the abluminal side with patient-derived pro-angiogenic saphenous 
vein pericytes (SVPs). 
As shown in the schematic (a) and the overlaid fluorescence microscopy image (b), the 
luminal side of the scaffold is mainly decorated with the Adh peptide (in red), to increase 
host endothelial cell (ECs) adhesion, migration and spreading. The outer layer presents 
mainly the Hep peptide (in green), which binds and present the SVP-produced growth factors 
(GFs). SEM image showing the size and distribution of the fibres in the scaffold (top view, 
c). Scale bars: 50 μm. 
 
  
 
Figure 2. Hep peptide binds and coordinates SVP-produced growth factors. Mean 
fluorescence (mean grey value) measuring the binding of heparin-FITC (a) and SVP-secreted 
VEGF-GFP (b) to unconjugated (CTL), Hep-conjugated (Hep) and dual peptide (Hep/Adh) 
scaffolds. Alamar blue (c) and representative images (d) show the increased HUVEC growth 
on VEGF loaded Hep mats. *P<0.05, **P<0.01. Scale bars: 500 μm. N = 3; n=3. 
  
 
Figure 3. Adh peptide specifically increases endothelial cell adhesion and growth. 
HUVECs were seeded on electrospun PCL scaffolds either unconjugated (CTL) or 
functionalised with Hep or Adh peptides. Cell density was measured at 48 hours post-seeding 
and is expressed as fold change over CTL (a, N = 4; n = 2). Representative images showing 
endothelial coverage on the different scaffolds (green: WGA-488, blue: DAPI, b). 
***P<0.001. Scale bars: 100 μm. 
 
  
 
Figure 4. The combination of bifunctional scaffold and SVP seeding increases 
endothelial coverage. Fluorescently labelled HUVECs were seeded on plain PCL (CTL) or 
dual peptide scaffolds (Hep/Adh), in presence or absence of pericytes (SVPs). Representative 
confocal micrographs showing the resulting coverage in each condition (a; green: WGA-488; 
blue: DAPI). Number of nuclei quantified at 48 hours is shown as a ratio over the control (b; 
plain PCL, no SVPs; N = 3; n = 2). **P<0.01 vs. CTL. Scale bar: 100 μm. 
 
  
 
Figure 5. Seeding of SVPs induces EC migration and gap closure. In a transwell™ 
migration assay, the seeding of SVPs (ECs+SVPs) in the lower chamber induces EC 
migration, as compared to EC spontaneous migration (ECs only). Relative migration 
quantification (a) and representative pictures are shown (b, blue: DAPI; N = 7; n = 4). The 
Hep/Adh scaffold was secured in a CellCulture™ crown, after seeding with SVPs on the 
  
lower side (ECs+SVPs) and a barrier was placed in the middle to prevent HUVEC adhesion 
and create a gap. HUVECs were plated on the top chamber and the barrier was removed to 
allow their migration (c). Gap closure was monitored at 48 hours, showing that seeding of the 
SVPs on the lower side of the scaffold promotes HUVEC gap invasion (d-g; grey scale: 
WGA-488; N=3). ***P<0.001. Scale bars: 400 μm (b, f and g) and 2 mm (d and e).  
 
Figure 6. Freezing of SVP-seeded PCL preserves cell viability and function. SVP seeded 
grafts were frozen and recovered, preserving over 65% viability (a) and 50% cell confluency 
(b). Freeze-thawed SVP were equally able to promote EC density, as compared to freshly 
plated SVP (c). SVP after the freeze and thaw process remain adherent to the scaffold (d, red: 
WGA-568) and promoted EC density (d, green: WGA-488). *P<0.05. Scale bars: 200 μm. N 
= 3. 
